If your SCLC patients have unexplained fatigue and
difficulty getting out of a chair or climbing stairs
Leave no stone unturned
Your patients may also have Cancer-Associated LEMS
LEMS=Lambert-Eaton myasthenic syndrome;
SCLC=small cell lung cancer;
VGCC-Ab=voltage-gated calcium channel antibody.
About Cancer-Associated LEMS1-3
Progressive and debilitating, Cancer-Associated LEMS is the most common antibody-mediated neurologic paraneoplastic syndrome in SCLC
Signs and Symptoms4
The signs and symptoms of Cancer-Associated LEMS may be hiding in your patients with SCLC, masked as either the symptoms of SCLC or the side effects of cancer treatments
Testing for Cancer-Associated LEMS3
A simple, inexpensive VGCC-Ab blood test can help you diagnose Cancer-Associated LEMS hiding in your patients with SCLC
Treatment Is Available5
There is an FDA-approved treatment for Cancer-Associated LEMS
Start your journey: About Cancer-Associated LEMS
/about/
References:
- Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006;4(6):631-638.
- Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
- Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:973808.
- Bebb DG, Murray C, Giannopoulou A, Felip E. Symptoms and experiences with small cell lung cancer: a mixed methods study of patients and caregivers. Pulm Ther. 2023;9:435-450.
- Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020;54(1):56-63.
- Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-363.
- Hartmann GG, Sage J. Small-cell lung cancer neuronal features and their implications for tumor progression, metastases, and therapy. Mol Cancer Res. 2024;22(9):787-795.
- Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2017;88:1-6.
- Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129-34.
- Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511-e520.
- ARUP Laboratories. Accessed August 2, 2025. https://ltd.aruplab.com/Tests/Pub/3002046
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 8, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Kunii E, Owaki S, Yamada K, et al. Lambert-Eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer. Intern Med. 2022;61:1739-1742.
- Giannoccaro MP, Avoni P, Liguori R. Presynaptic paraneoplastic disorders of the neuromuscular junction: an update. Brain Sci. 2021;11(8):1035.
- Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011; Appendix:1-4.
- Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530.
- Morrell D, Drapkin B, Shechter G, Grebla R. Lambert-Eaton myasthenic syndrome is underrecognized in small cell lung cancer: an analysis of real-world data. Presented as a poster at the International Association for the Study of Lung Cancer (IASLC) – WCLC Annual Meeting 2023. September 9-12, 2023, Singapore.
- Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003;998:500-508.
- Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011;3:a003947.
- Schampel A, Kuerten S. Danger: High voltage—the role of voltage-gated calcium channels in central nervous system pathology. Cells. 2017;6(4):43.
- Loser V, Vicino A, Théaudin M. Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice. Front Neurol. 2024;15:1495205.
- Alhammad RM, Alshamian Y, Alneseyan R, Al-Harbi TM, Ajhijab A, Alanazy MH. Clinical presentations, electrophysiologic features, and long-term follow-up in Lambert-Eaton myasthenic syndrome: a series of six patients. Front Neurol. 2024;15:1525155.
- Labcorp. Voltage-gated calcium channel antibody (VGCCA). Accessed August 16, 2025. https://www.labcorp.com/tests/140640/voltage-gated-calcium-channel-antibody-vgcca
- Kesner VG, Shin JO, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36(2):379-394.
- Silva T. Understanding lambert-eaton myasthenic syndrome: pathophysiology, diagnosis, and treatment. J Neurol Neurorehab Res. 2024;9(1):1-2.
- Ivanovski T, Miralles F. Lambert-Eaton myasthenic syndrome: early diagnosis is key. Degener Neurol Neuromuscul Dis. 2019;13:27-37.
